Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Enjoy this offer
* See conditions under "Our services"

Valuation: Medpace Holdings, Inc.

Capitalization 1.31TCr 0 0 0 0 0 0 0 0 0 0 0 0 P/E ratio 2026 *
26.9x
P/E ratio 2027 * 24.8x
Enterprise value 1.19TCr 0 0 0 0 0 0 0 0 0 0 0 0 EV / Sales 2026 *
4.3x
EV / Sales 2027 * 4x
Free-Float
80.38%
Yield 2026 *
-
Yield 2027 * -
1 day+0.80%
1 week+1.42%
Current month+2.41%
1 month+8.00%
3 months-2.70%
6 months-16.62%
Current year-18.47%
1 week 434.38
Extreme 434.38
466.22
1 month 403.46
Extreme 403.46
466.22
Current year 373
Extreme 373
628.92
1 year 294.07
Extreme 294.07
628.92
3 years 207.83
Extreme 207.83
628.92
5 years 126.94
Extreme 126.945
628.92
10 years 21.76
Extreme 21.76
628.92
Manager TitleAgeSince
Chief Executive Officer 69 01/07/1992
Director of Finance/CFO 51 01/08/2021
Chief Tech/Sci/R&D Officer 65 01/09/2017
Director TitleAgeSince
Chairman 69 01/07/1992
Director/Board Member 55 01/07/2016
Director/Board Member 72 01/07/2016
Date Insider Type Main position Quantity % Market Cap.
01/06Other

Executive/Senior Manager

16,197 0.0567%
28/05Fiscal year

Compliance Officer

49,047 0.1717%
15/05Free

Director

1,110 0.0039%
Change 5d. change 1-year change 3-years change Capi.($)
+0.80%+1.42%+54.44%+106.55% 1.31TCr
+0.76%-1.39%-14.67%-15.35% 4.3TCr
-0.50%-9.28%+261.38%+497.79% 3.16TCr
+0.13%-1.68%+20.59%-10.91% 3.07TCr
+0.26%-3.18%+5.84%+24.76% 3.01TCr
-7.00%-12.69%+6.72%+8.66% 2.25TCr
-0.06%+4.88%+11.17%+5.60% 1.32TCr
-2.20%-5.95% - - 1.28TCr
-1.26%-2.44%+108.39%+76.57% 1.22TCr
+1.87%+10.29%+9.44%-32.36% 1.17TCr
Average -0.72%-2.00%+51.48%+73.48% 2.21TCr
Weighted average by Cap. -0.64%-3.12%+52.25%+85.03%

Financials

2026 *2027 *
Net sales 277.11Cr 0 0 0 0 0 0 0 0 0 0 0 0 290.21Cr 0 0 0 0 0 0 0 0 0 0 0 0
Net income 49Cr 0 0 0 0 0 0 0 0 0 0 0 0 53Cr 0 0 0 0 0 0 0 0 0 0 0 0
Net Debt -116.15Cr -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -147.05Cr -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0
Logo Medpace Holdings, Inc.
Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
Employees
6,300
Date Price Change Volume
08/26/08 457.90 $ +0.80% 1,86,819
05/26/05 454.25 $ -0.97% 1,90,552
04/26/04 458.69 $ +1.75% 2,21,320
03/26/03 450.82 $ +1.17% 2,40,137
02/26/02 445.59 $ -1.30% 2,98,835
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
457.90USD
Average target price
442.83USD
Spread / Average Target
-3.29%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MEDP Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
BENEFIT NOW